(0.51%) 5 072.00 points
(0.40%) 38 221 points
(0.65%) 17 552 points
(0.63%) $79.50
(1.14%) $1.954
(0.70%) $2 327.20
(0.23%) $26.81
(1.42%) $968.50
(-0.02%) $0.933
(-0.08%) $11.02
(-0.08%) $0.798
(-0.26%) $93.02
-0.25% £ 976.60
Live Chart Being Loaded With Signals
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures...
Stats | |
---|---|
Tagesvolumen | 3.78M |
Durchschnittsvolumen | 3.66M |
Marktkapitalisierung | 8.54B |
EPS | £0 ( 2024-05-01 ) |
Last Dividend | £18.38 ( 2023-03-30 ) |
Next Dividend | £0 ( N/A ) |
P/E | 40.69 |
ATR14 | £0.953 (0.10%) |
Volumen Korrelation
Smith & Nephew plc Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Smith & Nephew plc Korrelation - Währung/Rohstoff
Smith & Nephew plc Finanzdaten
Annual | 2023 |
Umsatz: | £5.55B |
Bruttogewinn: | £3.82B (68.82 %) |
EPS: | £0.300 |
FY | 2023 |
Umsatz: | £5.55B |
Bruttogewinn: | £3.82B (68.82 %) |
EPS: | £0.300 |
FY | 2022 |
Umsatz: | £5.22B |
Bruttogewinn: | £3.68B (70.47 %) |
EPS: | £0.250 |
FY | 2021 |
Umsatz: | £5.21B |
Bruttogewinn: | £3.67B (70.40 %) |
EPS: | £0.598 |
Financial Reports:
No articles found.
Smith & Nephew plc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
£12.91 (N/A) |
£0 (N/A) |
£18.38 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | £3.45 | 1993-05-10 |
Last Dividend | £18.38 | 2023-03-30 |
Next Dividend | £0 | N/A |
Payout Date | 2023-05-17 | |
Next Payout Date | N/A | |
# dividends | 64 | -- |
Total Paid Out | £440.59 | -- |
Avg. Dividend % Per Year | 1.26% | -- |
Score | 4.16 | -- |
Div. Sustainability Score | 8.49 | |
Div.Growth Potential Score | 4.99 | |
Div. Directional Score | 6.74 | -- |
Year | Amount | Yield |
---|---|---|
1993 | £0 | 0.00% |
1994 | £0 | 0.00% |
1995 | £0 | 0.00% |
1996 | £0 | 0.00% |
1997 | £0 | 0.00% |
1998 | £0 | 0.00% |
1999 | £0 | 0.00% |
2000 | £0 | 0.00% |
2001 | £0 | 0.00% |
2002 | £0 | 0.00% |
2003 | £0 | 0.00% |
2004 | £0 | 0.00% |
2005 | £0 | 0.00% |
2006 | £0 | 0.00% |
2007 | £0 | 0.00% |
2008 | £0 | 0.00% |
2009 | £0 | 0.00% |
2010 | £0 | 0.00% |
2011 | £0 | 0.00% |
2012 | £0 | 0.00% |
2013 | £0 | 0.00% |
2014 | £0 | 0.00% |
2015 | £0 | 0.00% |
2016 | £0 | 0.00% |
2017 | £0 | 0.00% |
2018 | £26.91 | 1.93% |
2019 | £28.49 | 1.99% |
2020 | £29.73 | 1.62% |
2021 | £27.12 | 1.73% |
2022 | £31.31 | 2.40% |
2023 | £18.38 | 1.64% |
2024 | £0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
UTG.L | Dividend Knight | 2023-09-14 | Annually | 25 | 1.82% | |
MNP.L | Dividend Knight | 2023-07-06 | Quarterly | 35 | 0.71% | |
DFS.L | Dividend Knight | 2023-11-30 | Annually | 10 | 1.89% | |
SGE.L | Dividend Knight | 2023-06-01 | Semi-Annually | 32 | 1.64% | |
IEML.L | No Dividend Player | 2023-08-10 | Insufficient data to determine frequency | 2 | 1.30% | |
BME.L | Dividend King | 2023-06-29 | Semi-Annually | 11 | 4.74% | |
XPP.L | Dividend Knight | 2023-09-07 | Quarterly | 18 | 1.72% | |
NWOR.L | Dividend Knight | 2023-06-01 | Insufficient data to determine frequency | 2 | 0.88% | |
ENT.L | Dividend Junior | 2023-08-17 | Annually | 19 | 0.58% | |
SRE.L | Dividend Knight | 2023-07-13 | Semi-Annually | 18 | 2.26% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0474 | 1.500 | 9.05 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0263 | 1.200 | 9.12 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0503 | 1.500 | -0.552 | -0.828 | [0.1 - 1] |
payoutRatioTTM | 1.243 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 1.775 | 0.800 | 6.13 | 4.90 | [1 - 3] |
quickRatioTTM | 0.569 | 0.800 | -1.359 | -1.087 | [0.8 - 2.5] |
cashRatioTTM | 0.133 | 1.500 | -0.372 | -0.558 | [0.2 - 2] |
debtRatioTTM | 0.309 | -1.500 | 4.85 | -7.28 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.695 | 2.00 | 9.77 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.207 | 2.00 | 9.90 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.591 | -1.500 | 7.64 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.701 | 1.000 | 1.644 | 1.644 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.123 | 1.000 | 9.54 | 9.54 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.197 | 1.000 | -0.0159 | -0.0159 | [0.2 - 2] |
assetTurnoverTTM | 0.556 | 0.800 | 9.63 | 7.70 | [0.5 - 2] |
Total Score | 8.49 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 40.63 | 1.000 | 6.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0503 | 2.50 | -0.355 | -0.828 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.207 | 2.00 | 9.93 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.87 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.695 | 2.00 | 9.77 | 10.00 | [0 - 30] |
payoutRatioTTM | 1.243 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.110 | 1.000 | 9.76 | 0 | [0.1 - 0.5] |
Total Score | 4.99 |
Smith & Nephew plc
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.